List of Contents

Epigenomics Market Size, Share, and Trends 2024 to 2033

Epigenomics Market (By Product: Reagents, Kits, Instruments, Enzymes, Services; By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large non - coding RNA, MicroRNA modification, Chromatin structures; By Application: Oncology, Non oncology) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : May 2024
  • Report Code : 2342
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Epigenomics Market 

5.1. COVID-19 Landscape: Epigenomics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Epigenomics Market, By Product

8.1. Epigenomics Market, by Product, 2024-2033

8.1.1 Reagents

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Kits

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Kits

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Whole Genomic Amplification kit

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Bisulfite Conversion kit

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. RNA Sequencing Kit

8.1.6.1. Market Revenue and Forecast (2021-2033)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2021-2033)

8.1.8. Instruments

8.1.8.1. Market Revenue and Forecast (2021-2033)

8.1.9. Enzymes

8.1.9.1. Market Revenue and Forecast (2021-2033)

8.1.10. Services

8.1.10.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Epigenomics Market, By Technology

9.1. Epigenomics Market, by Technology, 2024-2033

9.1.1. DNA Methylation

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Histone Methylation

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Histone Acetylation

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Large non-coding RNA

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. MicroRNA Modification

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. Chromatin Structures

9.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Epigenomics Market, By Application 

10.1. Epigenomics Market, by Application, 2024-2033

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Non oncology

10.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Epigenomics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Forecast, by Technology (2021-2033)

11.1.3. Market Revenue and Forecast, by Application (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Technology (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Application (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Technology (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Application (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Forecast, by Technology (2021-2033)

11.2.3. Market Revenue and Forecast, by Application (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Technology (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Application (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Technology (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Application (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Technology (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Application (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Technology (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Application (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Forecast, by Technology (2021-2033)

11.3.3. Market Revenue and Forecast, by Application (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Technology (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Application (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Technology (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Application (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Technology (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Application (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Technology (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Application (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Forecast, by Technology (2021-2033)

11.4.3. Market Revenue and Forecast, by Application (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Technology (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Application (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Technology (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Application (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Technology (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Application (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Technology (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Application (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Forecast, by Technology (2021-2033)

11.5.3. Market Revenue and Forecast, by Application (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Technology (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Application (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Technology (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Application (2021-2033)

Chapter 12. Company Profiles

12.1. Thermo Fisher Scientific (US)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Merck KGaA (Germany)

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Illumina, Inc. (US)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. PacBio (US)

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Abcam plc (UK)

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Active Motif

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Bio-Rad Laboratories (US)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Promega Corporation (US)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. PerkinElmer (US)

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Qiagen (Germany)

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global epigenomics market size is expected to increase to USD 62.11 billion by 2033 from USD 14.7 billion in 2023.

The global epigenomics market is poised to grow at a CAGR of 15.5% from 2024 to 2033.

The major players operating in the epigenomics market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), F. Hoffmann-La Roche Ltd (Switzerland)

The amount of funds received for the purpose of research in epigenomics has increased in the recent years many new products are launched in the market, Increased use of the tricks that are epigenomics based for diagnosis purposes have also increased, the use of this technique for treating cancer is one of the major factors that will lead to the growth of the market.

The North America region contains the largest revenue share in the epigenomic market.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us